An observational study in Breast Cancer, sponsored by Centre Leon Berard. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-25.
Sponsored by Centre Leon Berard · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Breast Neoplasms by Centre Leon Berard — 5 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · Centre Leon Berard.
Among the 23 studies in Breast Neoplasms by Centre Leon Berard, this one is one of 2 that started in 2021, is one of 7 observational ones, and was the 16th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →5 of the 23 studies in Breast Neoplasms by Centre Leon Berard are open now, in 1 country. Recruiting first, the newest first:
Centre Leon Berard · Sites in France
Ages 18+ · Women only
Centre Leon Berard · Sites in France
Ages 18+ · Women only
Centre Leon Berard · Sites in France
Ages 18+ · Women only
Centre Leon Berard
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 98 across the 16 interventional studies, 160 across the 7 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Centre Leon Berard is the lead sponsor of 211 studies on the registry; 62 are open to participants now.
2 of the studies in Breast Neoplasms by Centre Leon Berard that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03571633Centre Leon BerardImpact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer | 2027-01 |
| NCT06906601Centre Leon BerardPreoperative Magnetic Tracking in Breast Surgery in France: French Medical-economic Study. | 2027-10-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Breast Neoplasms by Centre Leon Berard, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Monocentric, observational and prospective study in adult women having an early-stage breast cancer without genetic risk.
The main objective is to characterize quantitatively and qualitatively, after solitary confinement, the resident breast stem cells and the immune system cells infiltrated in the mammary gland in women:
Breast cancer is one of the most frequent and the second cause of mortality for women in the world. Breast is a complex organ which has several changes (puberty, pregnancy and menopause). These modifications are controlled by numerous signals as those transmitted by the oestrogens. They are possible through the presence of stem cells in the mammary gland which are able to reply to these signals and can be the target of alterations leading to cancer cells occurence. Breast tumors are composed of complex entities of different kinds of cancer and normal cells which constitute the tumor micro-environment including the immune system cells. This micro-environment transmits a lot of signals to cancer cells and particularly stem cells which can contribute to their survival, the tumor progression and interfere with the treatments efficacy.
The detection of the major deregulation of BMP2 synthesis by mammary micro-environment cells may be a reliable and early biomarker of carcinogens exposure and an indicator of a high risk of developing a luminal type breast cancer.
The immune micro-environment, which has an impact on solid cancer patients' survival, should be taken into consideration for new therapeutic strategies.
Some infiltrating tumour immune cells, as macrophages (TAM) or regulating T and B cells, have shown their key role in tumour escape and metastases apparition. It is relevant to associate the evaluation of immune infiltrate to the breast stem cells in early stage tumours since the literature suggests a functional interaction of these two cellular compartments, particularly in the glioblastoma and the prostate cancer. It seems that mammary stem cells are a major element in the comprehension of breast carcinogenesis but also in the possibilities of repairing the mammary tissue controlling the mammary carcinogenesis.
It is fundamental to clarify the role of stem cells and immunity. Our hypothesis is that breast stem cells are altered in women having a high risk of cancer progression. They would be responsible for a reduced activity of cellular repair and/or contribute to tumour development.
MACSSI project consists in isolating, quantifying and characterizing the breast stem cells and the isolated immune cells of samples obtained for the prophylactic mastectomy in women presenting different tumour progression risks.
The results will be compared to normal samples already collected in women who had a breast reduction.
Adult women having an early-stage breast cancer without genetic risk requiring a breast surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient requiring a breast surgery (total mastectomy) of an early stage tumour classified as :
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Isolation, quantification and characterization of breast stem and immune cells of samples obtained during the prophylactic mastectomy in women presenting different tumor progression risks.
To characterise quantitatively and qualitatively, after solitary confinement, the resident breast stem cells and the immune system cells infiltrated in the mammary gland according to the risk of breast cancer progression (group A and B)
Rate of stem and immune cells and phenotype analysis
Time frame: Within one month after inclusion (date of surgery)
Functional characterization, after solitary confinement, of stem cells and immune system cells from groups A and B
Functional test: mammosphere
Time frame: Within one month after inclusion (date of surgery)
Functional characterization, after solitary confinement, of stem cells and immune system cells from groups A and B
Functional test: TDLU
Time frame: Within one month after inclusion (date of surgery)
Functional characterization, after solitary confinement, of stem cells and immune system cells from groups A and B
Functional test: E-CFC - FACS
Time frame: Within one month after inclusion (date of surgery)
Determination of the stem cells role in the cellular regulation and repair activity
Functional tests
Time frame: Within one month after inclusion (date of surgery)
Determination of the efficacy of the immune systems cells found in the samples in the early stage of breast tumorigenesis
FACS
Time frame: Within one month after inclusion (date of surgery)
Evaluation of the role of breast stem and immune cells in the early stage development of a breast cancer: risk or protective factor ?
Functional tests: mammosphere, TDLU, E-CFC - FACS
Time frame: Within one month after inclusion (date of surgery)
Started Feb 2021 (actual). Primary completion is estimated for Feb 2024, 36 months after the start.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 36 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.